Group 1 - Citizens, Inc. will present at the Emerging Growth Virtual Conference on April 2, 2026, at 3:25 ET, with a live webcast available on the Company's Investor Relations website [1] - The webcast will be archived for future viewing, allowing investors to access the presentation at their convenience [1] Group 2 - Citizens, Inc. is a diversified financial services company specializing in life, living benefits, and final expense insurance, serving individuals and small businesses in the U.S., Latin America, and Asia [2] - The company operates two primary segments: International Insurance, focusing on U.S. Dollar denominated life insurance, and Domestic Insurance, which targets niche markets in the U.S. with final expense products [2] - Citizens, Inc. is included in the Russell 2000® and Russell 3000® indexes, indicating its significance in the market [2]

Core Viewpoint - Procter & Gamble (P&G) is facing analyst downgrades due to rising oil-related input costs linked to the Iran war, which the firm believes P&G and its peers cannot fully absorb [2][3]. Analyst Downgrade Details - TD Cowen has cut P&G's price target from $156 to $142 while maintaining a Hold rating, indicating limited upside potential from current share prices [2][3]. - The stock is currently trading around $144.72, reflecting a modest increase of 2.07% year-to-date, but a significant decline of 11.49% over the past month [3]. Financial Performance - P&G's Q2 FY2026 results showed core EPS of $1.88, surpassing the consensus estimate of $1.8569, but net sales of $22.21 billion fell short of the $22.29 billion estimate [5]. - Operating income decreased by 6.53% year-over-year to $5.366 billion, and net income dropped by 6.72% to $4.319 billion, highlighting challenges in revenue growth amid rising input costs [5]. Cost Pressures and Guidance - Management has projected approximately $400 million in after-tax tariff costs for FY2026 and maintained a core EPS guidance range of $6.83–$7.09, contingent on productivity gains and pricing strategies [6]. - TD Cowen expresses skepticism about the feasibility of achieving this guidance due to execution risks [6]. Market Sentiment and Comparisons - TD Cowen's target of $142 is significantly lower than the consensus analyst price target of $167.59, indicating a divergence in market sentiment with 14 Buy ratings versus nine Holds and one Sell [7]. - Other firms, such as Deutsche Bank and Erste Group, have also adjusted their targets downward, citing similar concerns regarding cost pressures and weak consumer demand [7]. Dividend Considerations - P&G is recognized as a Dividend King, having increased its dividend for 69 consecutive years, with a quarterly dividend of $1.0568 per share and a trailing yield of approximately 2.93% [8]. - Despite the dividend consistency, concerns about sticky input cost inflation and diminishing pricing power suggest that margin recovery may be slower than anticipated [8].

Group 1 - The UK banking industry is facing a significant increase in customer complaints, with 1.85 million complaints received in the first half of 2025, marking a 20% rise from the previous six months [1] - Complaints have remained consistently high over the years, indicating a persistent issue in the banking sector's ability to meet customer expectations [2] - The volume of complaints is putting pressure on banks, revealing a growing gap between customer expectations and the institutions' capabilities [2] Group 2 - Fraud is a contributing factor to the rising complaints, with £629.3 million lost to fraud in the first half of 2025 across 2.09 million cases [3] - Complaints are not the root cause of issues but rather a reflection of how effectively banks operate and communicate with customers [4] - Many complaints are valid concerns that could have been addressed earlier in the customer journey, as indicated by the 57% uphold rate of complaints [6] Group 3 - The complaint handling processes in banks are often outdated, relying heavily on manual work and leading to delays and inconsistencies [5] - Large banks face challenges in maintaining consistency due to their operations across multiple product lines and jurisdictions, often on legacy infrastructure [7] - Regulatory expectations have increased, with the Consumer Duty requiring firms to demonstrate fair outcomes and consistent treatment of customers, which many existing processes are not equipped to handle [8]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to alleged violations of federal securities laws related to misleading statements about the efficacy of its drug setrusumab in treating Osteogenesis Imperfecta [2][4]. Group 1: Allegations and Legal Actions - The complaint alleges that Ultragenyx and its executives misrepresented their knowledge regarding the effects of setrusumab, creating a false impression of reliability while downplaying risks associated with the Phase III Orbit study [4]. - The company reportedly failed to disclose that the optimism surrounding the Phase III Orbit study's results was unfounded, as it relied on Phase II results without a placebo control group, which could have led to misleading conclusions about the drug's effectiveness [4]. - Following the announcement on July 9, 2025, that the Phase III Orbit study did not achieve statistical significance, Ultragenyx's stock price fell by over 25% [5]. Group 2: Study Results and Stock Impact - On December 29, 2025, Ultragenyx disclosed that both the Phase III Orbit and Cosmic studies did not meet primary endpoints for reducing annualized clinical fracture rates compared to placebo or bisphosphonates, attributing the failure to a low fracture rate in the placebo group [6]. - This announcement resulted in a further decline of over 42% in Ultragenyx's stock price [7]. Group 3: Class Action Details - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Ultragenyx is April 6, 2026 [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. due to allegations of violations of federal securities laws related to misleading statements about the efficacy and safety of its RGX-111 trial study [3]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against REGENXBIO [2]. - The complaint alleges that REGENXBIO and its executives made false and/or misleading statements and failed to disclose material adverse facts concerning the RGX-111 trial [3]. Group 2: Clinical Hold and Stock Impact - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 investigational gene therapy following a case of neoplasm in a trial participant [4]. - The FDA also placed a clinical hold on RGX-121 for similar reasons, leading to a stock price drop of $2.40 per share, or 17.9%, closing at $11.01 per share on the same day [4]. Group 3: Investor Communication - Faruqi & Faruqi encourages investors who suffered losses in REGENXBIO to contact them directly to discuss their legal options [1]. - The firm is also seeking information regarding REGENXBIO's conduct from whistleblowers, former employees, and shareholders [6].

Group 1 - Paulig has sold its Risenta brand to Midsona for Skr45 million ($4.7 million) as part of its strategy to focus on world foods and Tex Mex [1][2] - The sale includes Risenta's brand, intellectual property, associated business, and production lines, but does not involve transferring any staff to Midsona [2][3] - Midsona views the acquisition as a way to strengthen its position in the healthy foods market in Sweden, expecting the deal to increase its EBIT margin and earnings per share, while adding around Skr130 million in annual revenue [3] Group 2 - Paulig has been reshaping its manufacturing footprint, including plans to end production at a spices plant in Mölndal and shift operations to Estonia due to higher input costs [4] - The company announced a €12 million ($14.1 million) investment to expand capacity at its Berga facility in Barcelona, including a new flour tortilla line to meet growing global demand for Tex-Mex products [4]

Core Viewpoint - James Hardie expands its strategic agreement with CBUSA, enhancing access to preferred products for custom builders [1] Group 1: Company Overview - James Hardie is a leader in exterior design solutions in North America [1] - The company has a long-standing relationship with CBUSA, the largest group purchasing organization for custom home builders in the U.S. [1] Group 2: Agreement Details - The new three-year exclusive deal will benefit CBUSA's network of nearly 1,000 custom builders [1] - Builders will gain access to preferred products, including TimberTech®, the top brand in premium composite and PVC decking and railing solutions [1]

Core Viewpoint - Jefferies downgraded Rockwell Automation from Buy to Hold, reducing the price target from $490 to $380 due to concerns over AI disintermediation impacting future growth potential [2][4]. Company Performance - Rockwell Automation is currently trading at approximately $348.51, reflecting a year-to-date loss of nearly 13% and significantly below its 52-week high of $438.72 [3]. - In Q1 FY2026, Rockwell reported an EPS of $2.75, exceeding the consensus estimate of $2.48, with revenue of $2.105 billion, representing an 11.8% year-over-year growth [7]. - The Software & Control segment, closely linked to AI developments, saw its operating margin increase to 31.2% from 25.1% in the previous year, with organic growth of 17% [7]. Valuation Concerns - Jefferies highlighted that Rockwell's current P/E ratio stands at 39.8 and a PEG ratio of 4.53, indicating limited room for error if growth slows or competitive dynamics change [6]. - The firm expressed that the valuation is already reflecting Rockwell's strong position in reshoring and onshoring, suggesting that the positive narrative is priced into the stock [5]. Future Outlook - The company has provided FY2026 organic sales growth guidance of 2%-6%, with a midpoint of 4%, which Jefferies considers insufficient to justify the current valuation multiple [7]. - The Lifecycle Services segment reported a decline in organic growth of -6% in Q1, and free cash flow decreased by 41.98% year-over-year [7]. Market Sentiment - Despite the downgrade, the broader analyst community remains positive, with a consensus target price of $431.37 based on 30 ratings, including 11 Buy and 14 Hold recommendations [8]. - The stock has decreased by 15.44% over the past month, indicating that the market is already grappling with the implications of AI disruption on Rockwell's business model [9].

Fund Performance - Platinum International Technology Fund achieved a 3% return in Q4 2025 and a 13.1% return for the entire year, outperforming the benchmark returns of 2.5% and 12.4% respectively [1] - The depreciation of the U.S. Dollar negatively impacted both the Fund and Benchmark returns when measured in Australian dollars [1] Market Environment - The market was characterized as 'risk-on', with defensive sectors such as Real Estate and Consumer Staples underperforming, while discretionary consumer businesses showed mixed results [1] - For 2026, the firm anticipates a similar investment environment as in 2025 and 2024, aiming to avoid extreme events [1] Company Focus - Jacobs Solutions Inc. (NYSE:J) is highlighted as a key stock, providing infrastructure and advanced facilities, with a market capitalization of $14.74 billion [2] - The stock of Jacobs Solutions Inc. experienced a one-month return of -10.14% and a 52-week gain of 3.37% [2] Investment Outlook - Jacobs Solutions Inc., along with Microsoft and Uber, detracted from the Fund's quarterly returns by between 0.5% and 0.8% each, but the company is viewed positively for the long term [3] - The engineering services industry is facing potential disruption from AI, but Jacobs Solutions is expected to be a net beneficiary of the AI revolution, with management actively investing in AI to enhance efficiencies [4][5]

Market Overview - Major indices are experiencing a rally, with the Dow up 455 points (approximately 1%), the Nasdaq up 187 points (almost 1%), and the S&P up 59 points (almost 1%) [1] - Wall Street is concluding its worst quarter in four years, with major indices down 7 to 8% over the last three months [1] - Oil prices have surged over 50% since the onset of the war on February 28th [1] Oil Prices and Economic Impact - Current trading prices for Brent oil are at $115.58, up 2.5%, and crude oil at $104.14, up 1.3% [2] - The Gulf region's economic significance is highlighted, with jet fuel prices in Asia having more than doubled [7] - A prolonged period of elevated oil prices could lead to significant global economic issues, particularly if it extends beyond a few weeks [8] Economic Analysis - Historical analysis indicates that it takes multiple factors to push a diversified economy into recession, with oil price spikes being one of many potential contributors [5][11] - The likelihood of an energy-related recession in the U.S. is estimated at 10% in any given year, based on historical data [10] - Central banks' responses to inflationary pressures from energy price shocks can exacerbate economic contractions [15][16] Investment Strategy - Maintaining a diversified investment portfolio tailored to individual risk profiles is recommended as a prudent strategy during economic fluctuations [19] - Historical lessons suggest that while recessions cannot be avoided, poor policy decisions can worsen their impact [20][21]